Clinical Trial Update: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial investigating elacestrant for estrogen receptor-positive, HER2-negative breast cancer with ctDNA relapse (TREAT ctDNA) is currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer
• Stage Iib Breast Cancer

Drugs mentioned

• Elacestrant (elacestrant)

Snippet

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC | Conditions: ER-positive Breast Cancer, HER2-negative Breast Cancer | Phase 3 | Status: RECRUITING